Inqovi is a medication that is used to treat certain types of blood cancers, specifically myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). It is a combination of two active ingredients, decitabine and cedazuridine, which work together to inhibit the growth of cancer cells.

Decitabine is a type of chemotherapy drug that works by interfering with the DNA replication process in cancer cells, ultimately leading to their death. Cedazuridine helps to increase the levels of decitabine in the blood, allowing for a more consistent and effective treatment.

Inqovi is typically taken orally once daily for five days in a row, followed by a rest period of two days. This treatment cycle is repeated every 28 days. It is important to follow the dosing schedule provided by your healthcare provider to ensure the best possible outcome.

As with any medication, Inqovi may cause side effects. Common side effects include nausea, vomiting, diarrhea, fatigue, and low blood cell counts. It is important to report any side effects to your healthcare provider so that they can be properly managed.

Before starting treatment with Inqovi, it is important to discuss your medical history and any other medications you are taking with your healthcare provider. They will be able to determine if Inqovi is the right treatment option for you.

Overall, Inqovi is a valuable treatment option for individuals with MDS or AML. It has shown to be effective in slowing the progression of these diseases and improving overall survival rates. If you have been prescribed Inqovi, be sure to take it as directed and communicate with your healthcare provider throughout your treatment journey.